Molecular and regional targets of cocaine in primate brain: Liberation from prosaic views

Addiction Biology

Volumn 5, Issue 3, 2000, Pages 351-359

  Madras, Bertha K ^a   Miller, Gregory M ^a   Meltzer, Peter C ^a   Brownell, Anna Liisa ^a   Fischman, Alan J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE TRANSPORTER;

BINDING SITE; COCAINE DEPENDENCE; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; EUPHORIA; HUMAN; NEUROBIOLOGY; PRIMATE; PRIORITY JOURNAL;

EID: 0033911020     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2000.tb00202.x     Document Type: Conference Paper

References (49)

1. 1. Nestler EJ, Kelz MB, Chen J. Delta Fos B: a molecular mediator of long-term neural and behavioral plasticity. Brain Res 1999;835:10-17.
2. 2. Carlezon WA Jr, Thome J, Olson VG et al. Regulation of cocaine reward by CREB. Science 1998;282:2272-5.
3. 3. Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997;7:713-19.
4. 4. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991;251:1580-6.
5. 5. Hurd YL, Kehr J, Ungerstedt U. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J Neurochem 1988;51:1314-16.
6. 6. Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 1996;17:260-4.
7. 7. Madras BK. Cocaine binding sites in monkey brain regions implicated in cocaine self-administration. Annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1989.
8. 8. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol 1989; 36:518-24.
9. 9. Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 1989;251:131-41.
10. 10. Madras, BK and Kaufman, MJ. Cocaine accumulates in dopamine-rich regions of primate brain after i.v. administration: comparison with mazindol distribution. Synapse 1994;18:261-75.
11. 11. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-12.
12. 12. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998;3:386-96.
13. 13. Church WH, Justice JB Jr, Byrd LD. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol 1987;139:345-8.
14. 14. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8.
15. 15. Kennedy LT, Hanbauer l. Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J Neurochem 1983;41:172-8.
16. 16. Reith ME, Meisler BE, Sershen H, Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 1986;35:1123-9.
17. 17. Schoemaker H, Pimoule C, Arbilla S, Scatton B, Javoy-Agid F, Langer SZ. Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 1985;329:227-35.
18. 18. Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989;251:150-5.
19. 19. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-23.
20. 20. Spealman RD, Madras BK, Bergman J. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 1989;251: 142-9.
21. 21. Kaufman MJ, Madras BK. Distribution of cocaine recognition sites in monkey brain: II. Ex vivo autoradiography with [3H]CFT and [125I]RTI-55. Synapse 1992;12:99-111.
22. 22. Volkow ND, Wang GJ, Fischman MW et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-30.
23. 23. Volkow ND, Wang GJ, Fowler JS et al. Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc Natl Acad Sci USA 1996;93:10388-92.
24. 24. Volkow ND, Ding YS, Fowler JS, Wang GJ. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 1996; 15:55-71.
25. 25. Sorg BA, Davidson DL, Kalivas PW, Prasad BM. Repeated daily cocaine alters subsequent cocaine-induced increase of extracellular dopamine in the medial prefrontal cortex. J Pharmacol Exp Ther 1997;281:54-61.
26. 26. Rocha BA, Fumagalli F, Gainetdinov RR et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998;1: 132-7.
27. 27. Volkow ND, Wang GJ, Fowler JS et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 1999;288:14-20.
28. 28. Sora I, Wichems C, Takahashi N et al. Cocaine reward models: conditioned place preference can be established in dopamine and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998;95:7699-704.
29. 29. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994;269: 15985-8.
30. 30. Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol 1995;48:1030-7.
31. 31. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 1992;89:7782-5.
32. 32. Kitayama S, Monta K, Dohi T, Wang JB, Davis SC, Uhl GR. Dissection of dopamine and cocaine binding sites on the rat dopamine transporter expressed in COS cells. Ann NY Acad Sci 1996;801:388-93.
33. 33. Ferrer JV, Javitch JA. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci USA 1998;95:9238-43.
34. 34. Lee FJ, Pristupa ZB, Ciliax BJ, Levey AI, Niznik HB. The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. J Biol Chem 1996;271:20885-94.
35. 35. Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 1999;56:434-47.
36. 36. Litten RZ, Allen JP. Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. J Subst Abuse Treat 1999; 16:105-12.
37. 37. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354: 2132-3.
38. 38. Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999;42:2721-36.
39. 39. Mendelson JH, Mello NK. Drug therapy: management of abuse and dependence. N Engl J Med 1996;334:965-72.
40. 40. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RA. Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 1987;84:4384-8.
41. 41. Madras BK, Pristupa ZB, Niznik HB et al. Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse 1996;24: 340-8.
42. 42. Meltzer PC, Liang AY, Blundell P et al. 2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J Med Chem 1997;40:2661-73.
43. 43. Meltzer PC, Liang AY, Brownell AL, Elmaleh DR, Madras BK. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem 1993; 36:855-62.
44. 44. Miller GM, Gracz LM, Goulet M et al. Point mutations of the human dopamine transporter (hdat) reveal differential binding of an amine and a non-amine ligand. Soc Neurosci Abstr 1999;25:283.
45. 45. Madras BK, Miller G, George S, O'Dowd B, Meltzer PC. Non-amines: a new generation of monoamine reuptake (dopamine, serotonin transporter) inhibitors. Soc Neurosci Abstr 1998; 4:278.
46. 46. De La Garza R II, Meltzer PC, Madras BK. Nonamine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain. Synapse 1999;34:20-7.
47. 47. Madras BK, Fahey MA, Akasofu K, Livni E, Jenkins B, Brownell A-L. Are monoamine transporters the only significant targets of cocaine in the brain? Soc Neurosci Abstr 1999; 25:1298.
48. 48. Fowler JS, Volkow ND, Wolf AP et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7.
49. 49. Madras BK, Livni E, Jenkins B, Brownell A-L. Prolonged occupancy of [11C]cocaine in orbitofrontal cortex of primate brain. CPDD, 1999, in press.